Medical Xpress

MARCH 15, 2023

Colorectal cancer is a cancer of the lower digestive system, which includes the colon and the rectum. If you feel like you are hearing a lot about this topic lately, it's because March is Colorectal Cancer Awareness Month. The goal is to increase awareness and encourage people 45 and over to get screened.

74

74

Pharmaceutical Technology

DECEMBER 8, 2022

Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer. On infusing back to the patient, this approach aids the T cells in detecting and killing cancer cells. . Topic sponsors are not involved in the creation of editorial content. Free Whitepaper.

Licensing 305

Licensing Licensing Gene Therapy Gene 305

Sciensano

MARCH 7, 2024

The Cancer Centre of Sciensano is delighted to announce to you the launch of the Beating Cancer Belgium Podcast , a platform dedicated to shedding light on cancer control and prevention in Belgium. This podcast is internally produced by Sciensano’s Cancer Centre.

52

52

Pharmaceutical Technology

APRIL 14, 2023

The company and the researchers, with Professor Krishanu Saha as principal investigator (PI) and Dr Christian Capitini as co-PI, will develop a GD2 CAR T-cell therapeutic candidate to treat neuroblastoma, a cancer type that generally affects young children. Topic sponsors are not involved in the creation of editorial content.

In-Vivo 264

In-Vivo Gene Therapy In-Vitro Engineer 264

Pharmaceutical Technology

JANUARY 17, 2023

The Spanish Association Against Cancer (AECC) provided funding for the new STAb therapy development. The future in cancer and leukaemia research lies in the creation of personalised therapies that provide options for all those who today find no alternative to conventional therapies. STAb-T therapy is on this path.”. Free Whitepaper.

Development 276

Development Gene Therapy Antibody Gene 276

ACRP blog

SEPTEMBER 13, 2023

Cancer incidence in Latinos is on the rise,” Nemecek points out, “and their risk of poor outcomes and mortalities is high due to socioeconomic disparities. The information from these forums was then used to create a series of educational audiovisual capsules covering cancer topics.

Clinical Trials 132

Clinical Trials Clinical Trials Trials Nurses 132

Scienmag

JUNE 17, 2022

June 17, 2022] — The National Comprehensive Cancer Network® (NCCN®) convened an oncology policy summit in Washington D.C. today on the topic of building a workplace that includes support for people with cancer and their caregivers. WASHINGTON, D.C.

77

77

Pharmaceutical Technology

SEPTEMBER 29, 2022

Scribe Therapeutics and Sanofi have signed a strategic partnership to expedite the development of breakthrough clustered regularly interspaced short palindromic repeats (CRISPR)-based cell therapies for cancer. Topic sponsors are not involved in the creation of editorial content.

Development 130

Development In-Vivo Genome Genomics 130

Pharmaceutical Technology

MAY 1, 2023

Under the deal terms, Shunxi will have licence to develop, manufacture, and commercialise CTH-004 to treat several solid tumours including ovarian cancer in Greater China, including Hong Kong, Taiwan, Mainland China, and Macao. In animal models of ovarian cancer, it demonstrated promising results.

Gene Therapy 130

Gene Therapy Gene Development Clinical Trials 130

Scienmag

JUNE 28, 2021

touch on topics of chronic inflammation, aging, and increased blood cancer risk Credit: CU Cancer Center Two recent collaborative publications by CU Cancer Center members provide insights into how chronic inflammation can serve as a key factor in the development of leukemia and other blood cancers. […].

Research 81

Research Development Genetics Medicine 81

Pharmaceutical Technology

APRIL 20, 2023

Circio aims to develop new circRNA medicines initially for cancer, then plans to expand rapidly into vaccines and gene therapy. CircAde is said to be the most advanced therapeutic concept, and leverages the company’s experience in oncolytic viruses to use engineered adenoviruses to deliver circRNA to cancer cells.

Gene Therapy 240

Gene Therapy RNA Gene Engineer 240

Pharmaceutical Technology

APRIL 21, 2023

Samyang has entered into a strategic partnership agreement with LG Chem to develop new cancer therapeutics using Samyang’s technology, NanoReady. LG Chem will use the technology for the development of innovative mRNA-based cancer therapeutics with maximised therapeutic efficacy.

Development 130

Development Gene Therapy Drug Delivery Gene 130

Triage Cancer

MARCH 4, 2021

Practical Guide to Cancer Rights and Legal & Financial Navigation Program. Navigating the legal and practical issues that may arise following a cancer diagnosis can be confusing. Practical Guide to Cancer Rights: Navigating Employment, Insurance, & Finances. Disability Insurance Options. financial toxicity). .

Development 98

Development 98

Pharmaceutical Technology

FEBRUARY 19, 2023

Danburstotug is under clinical development by Sorrento Therapeutics and currently in Phase III for Cervical Cancer. According to GlobalData, Phase III drugs for Cervical Cancer have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Development 100

XTalks

JANUARY 27, 2023

” In March 2022, Nobelpharma received approval from the US Food and Drug Administration (FDA) for its topical treatment for facial angiofibroma called Hyftor (sirolimus topical gel) 0.2 Hyftor became the first FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis.

Life Science 98

Life Science Genetic Disease FDA Approval Marketing 98

Pharmaceutical Technology

OCTOBER 14, 2022

The two companies will aim to improve the manufacturing and analytic procedures used to develop personalised cell and gene therapies to treat cancer patients. We look forward to supporting aCGT and their initiatives, including the next-generation cell therapies for the cancer-focused HEALED Consortium.”.

Gene Therapy 130

Gene Therapy Gene Development Manufacturing 130

Pharmaceutical Technology

JUNE 7, 2023

Acepodia will use the proceeds from the Series D round to advance its cell therapies pipeline, including ACE1831 and ACE2016, to treat solid tumours and haematologic cancers. ACE1931 is an off-the-shelf therapy targeting CD20-expressing haematological cancers. Topic sponsors are not involved in the creation of editorial content.

Gene Therapy 147

Gene Therapy Gene Development Antibody 147

FDA Law Blog

NOVEMBER 28, 2023

The notice ( here ) indicates that FDA plans for the panel to “discuss and make recommendations on the design of multi-cancer detection (MCD) in vitro diagnostic devices (tests) as well as potential study designs and study outcomes of interest that could inform the assessment of the probable benefits and risks of MCD screening tests.”

In-Vitro 64

In-Vitro Genetics Regulation Development 64

pharmaphorum

JUNE 4, 2021

The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of safe and effective therapies to treat prostate cancer. Bringing theranostics to prostate cancer.

Development 98

Development Drugs Clinical Development 98

Pharmaceutical Technology

NOVEMBER 29, 2022

Neogene focuses on discovering, developing and producing next-generation T-cell receptor therapies (TCR-Ts) that provide a new cell therapy approach for fighting cancer. TCR-Ts can detect intracellular targets such as cancer-specific mutations to unlock targets which were not accessible earlier using cell therapies. Free Whitepaper.

Gene Therapy 279

Gene Therapy Gene Development Manufacturing 279

Pharmaceutical Technology

MAY 24, 2023

CohBar has entered into a definitive merger deal with Morphogenesis to advance a late-stage clinical immuno-oncology pipeline of therapies to overcome resistance to cancer immunotherapy. Morphogenesis’s technologies include Immune Fx (IFx) personalised cancer vaccines and tumour microenvironment (TME) modulators.

Gene Therapy 130

Gene Therapy In-Vivo In-Vitro Immune Response 130

Pharmaceutical Technology

SEPTEMBER 30, 2022

Phase I clinical trials of SynKIR-110 in mesothelin-expressing mesothelioma, cholangiocarcinoma and ovarian cancer patients will begin in the first quarter of next year. Mesothelioma is a rare cancer type that impacts the lining of the chest or abdominal cavities. Topic sponsors are not involved in the creation of editorial content.

Drugs 130

Drugs Gene Therapy Trials Clinical Trials 130

pharmaphorum

JANUARY 18, 2022

Targeted agents and immunotherapies are two of the most promising areas for significant advancements in cancer treatment. Envision Pharma’s scientific solutions division lead Rebecca Goldstein, discusses this topic and other developments that cancer patients and their loved ones should be paying attention to.

Development 98

Development Drugs Research 98

Pharmaceutical Technology

NOVEMBER 16, 2022

Affini-T Therapeutics chief technical officer Kim Nguyen said: “Affini-T is pioneering novel T cell therapy approaches to treat solid tumour cancers by striking at the core of tumour biology, which entails leveraging the most advanced tools and techniques in cell engineering.

Development 246

Development Gene Therapy Engineer Gene Editing 246

Pharmaceutical Technology

JANUARY 10, 2023

Boehringer Ingelheim has entered a strategic partnership and licensing agreement with 3T Biosciences for the discovery and development of next-generation cancer immunotherapies. 3T Biosciences president and CEO Stefan Scherer said: “3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. “By

Gene Therapy 130

Gene Therapy Sales Gene Production 130

Triage Cancer

OCTOBER 13, 2020

Depending on which state you live in, your state laws may provide additional protections and benefits for individuals diagnosed with cancer and caregivers. Triage Cancer offers a Chart of State Laws to access location-specific information on topics like: Employment. Other cancer-related state laws. Taking Time Off Work.

Clinical Trials 52

Clinical Trials Clinical Trials Trials 52

Drug Discovery World

JANUARY 20, 2023

This is an extraordinarily exciting time to be involved in precision medicine for cancer.

Medicine 52

Medicine Research Drugs Development 52

Pharmaceutical Technology

FEBRUARY 9, 2023

Under the agreement, Asieris will use the advanced RNA modulation technologies, BindeR and SpliceR, of ReviR for identifying and developing new therapies that target RNA for cancer treatment. The company is focused on developing RNA-targeting small molecule therapies to treat cancer and other serious genetically defined diseases.

Development 241

Development RNA Gene Therapy Genetics 241

Pharmaceutical Technology

OCTOBER 13, 2022

Vita Therapeutics has raised $31m in a Series B financing round for the development of cell therapies for neuromuscular diseases and cancers. Topic sponsors are not involved in the creation of editorial content. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Development 130

Development Gene Editing Gene Gene Therapy 130

Drug Discovery World

JANUARY 20, 2023

Precision medicine uses information about an individual’s genes, proteins, and environment to prevent, diagnose, and treat diseases, including cancer. Standard treatment for some cancers now include genotyping or molecular imaging in living patients.

Medicine 52

Medicine Genotype Protein RNA 52

Drug Discovery World

JANUARY 10, 2023

The American Association for Cancer Research (AACR) Annual Meeting 2023 will be held April 14-19 at the Orange County Convention Center in Orlando, Florida. The post AACR meeting will share the latest advances in cancer science appeared first on Drug Discovery World (DDW). View the full programme here.

Immune Response 52

Immune Response Clinical Trials Clinical Trials Research 52

Pharmaceutical Technology

MAY 19, 2023

“We are pioneering the convergence of immunology and RNA science to build a clinical-stage portfolio of products, starting with the significant unmet needs of cancer patients. “We Topic sponsors are not involved in the creation of editorial content. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

In-Vivo 246

In-Vivo Gene Therapy Gene RNA 246

Pharmaceutical Technology

DECEMBER 1, 2022

A clinical-stage biopharmaceutical firm, Liminatus focuses on the development of new therapies for cancer that utilises the immune system of the body to detect and fight cancer cells. It can induce immune responses against Guanylyl Cyclase C (GCC) expressing colorectal, pancreatic, gastric and oesophageal cancers.

Gene Therapy 130

Gene Therapy Clinical Trials Clinical Trials Immune Response 130

XTalks

OCTOBER 19, 2021

With October being Breast Cancer Awareness Month, celebrities are joining campaigns to help raise awareness of the disease. She also highlighted how breast cancer is more fatal for Black women, and how she wants to change that. We didn’t know she had cancer, so she was in the hospital dying but she’d probably had it for a while.

Clinical Trials 98

Clinical Trials Clinical Trials FDA Approval Trials 98

Pharmaceutical Technology

JANUARY 4, 2023

The company is currently leveraging synthetic biology and non-viral cell engineering to develop cryopreserved CAR-NK cell therapies that can treat challenging cancers such as solid tumours. These CAR-NK cell therapies combine new functional attributes with the NK cells’ inherent cancer-fighting properties. Free Whitepaper.

Engineer 130

Engineer Gene Therapy Gene Development 130

Pharmaceutical Technology

APRIL 27, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has recommended two new personalised immunotherapy therapies from Kite Pharma to treat aggressive forms of blood cancer for the Cancer Drugs Fund (CDF). Established in 2011, the CDF is a source of funding to increase patient access to cancer drugs in the UK.

Gene Therapy 147

Gene Therapy Gene Clinical Trials Clinical Trials 147

pharmaphorum

AUGUST 25, 2022

Today on the pharmaphorum podcast, Editor in Chief Jonah Comstock welcomes Hedi Ben Brahim and Eric Quéméneur, CEO and chief science officer respectively of Transgene, to discuss cancer vaccines in general and Transgene’s recent work in the space in particular. . Podbean. .

Vaccination 52

Vaccination Vaccine Immune Response Drugs 52